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1 Tel.: +91 7838878710.Suneeta Dubey a,⇑, Vijeta Sharma a,1, Anugya Agrawal a, Lokesh Chauhan a, Gordon Douglas bAbstractPurpose: To evaluate the safety and efficacy of Ahmed glaucoma valve (AGV) implantation in refractory glaucoma in Northern
Indian eyes.
Background: The success rate of trabeculectomy remains low in cases of refractory glaucoma even with the use of antifibrotics.
Glaucoma drainage devices have proven to be more efficacious in reducing intraocular pressure (IOP) in these glaucomas.
Methods: Retrospective records of 55 consecutive patients who underwent AGV implantation at Dr. Shroff’s Charity Eye Hospital,
New Delhi, India from January 2003 to December 2012 were reviewed. Pre-operative data included age, gender, eye laterality,
specific diagnosis, number of anti-glaucoma medications, number of prior incisional surgeries, visual acuity and IOP on medical
treatment. Postoperative data included visual acuity and IOP on day one, 1 week, 1 month, 3 months, 6 months, 1 year and yearly
thereafter, number of anti-glaucoma medications, any complication or additional surgical intervention required. Success was
defined as IOP >5 and <22 mmHg with or without treatment.
Results: Mean IOP decreased from 39.71 ± 8.99 pre-operatively to 17.52 ± 5.72 mmHg at last follow-up (p < 0.001) and number of
medications reduced from 3.27 ± 0.84 to 1.25 ± 0.88 (p < 0.001). Visual acuity remained within one Snellen line or improved at last
follow-up in 47 cases (85.4%). The cumulative probability of success was 85.45% at 1 year and 79.63% at 3 years. The incidence of
post-operative complications was 25.45%.
Conclusion: AGV implantation has proven to be safe and is effective in controlling IOP in refractory glaucoma in Northern Indian
eyes.
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Glaucoma is one of the leading causes of blindness world-
wide.1 Refractory glaucoma is the term used to define any
kind of glaucoma that does not respond to medical or con-
ventional surgical treatment.1–4 The most commonly per-
formed surgical procedure for glaucoma is trabeculectomywith or without anti-fibrotic agents.5–10 Various modifications
have been tried to improve the success of trabeculectomy
such as use of anti-fibrotic agents and mechanical barriers,
but still the success rate remains low in cases of refractory
glaucoma. Glaucoma drainage devices (GDDs) have proven
to be more efficacious in reducing intraocular pressure
(IOP) in refractory glaucomas.11,12e:
al.com
grawal),
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with a long silicone tube attached to a thin acrylic plate.13,14
All currently available GDDs are based on the concept of the
Molteno implant with various modifications such as introduc-
tion of a valve mechanism or variations in surface area of the
end plate.
The Ahmed glaucoma valve (AGV) (New World Medical
Inc., Rancho Cucamonga, CA, USA) is a shunt device with a
built-in Venturi valve which opens at a specific level of IOP,
thus reducing the chances of hypotony in the early post-oper-
ative period.15 The valve may act as a potential site for
obstruction by inflammatory debris, especially in Asian eyes
that are known to have more severe reactions.16 The purpose
of the present study is to evaluate the safety and efficacy of
AGV implants in refractory glaucomas in a Northern Indian
population.Materials and methods
This is a retrospective cohort study of 55 patients with
refractory glaucoma, who underwent AGV implantation at
Dr. Shroff’s Charity Eye Hospital, New Delhi, India from Jan-
uary 2003 to December 2012.
Patients of all ages and both genders with refractory glau-
coma unresponsive to conventional medical and surgical
therapy or significant conjunctival scarring or inflammation
precluding trabeculectomy were included. Patients were
excluded if they had irregular or inadequate (<3 months) fol-
low up. Two patients were excluded because of irregular fol-
low-up from a pool of 57 patients. The Institutional review
board approval was obtained for this research. Further, writ-
ten informed consent also was obtained from each
participant.
Data collection
Pre-operative data were collected from patients’ records
including age at the time of surgery, gender, eye laterality,
specific glaucoma diagnosis, number of anti-glaucoma med-
ications used pre-operatively, number of prior incisional sur-
geries, visual acuity and pre-operative IOP on medical
treatment. Postoperative data included visual acuity and
IOP on day one, 1 month, 3 months, 6 months, 1 year and
yearly thereafter, number of anti-glaucoma medications used
post-operatively, any significant intra-operative or post-oper-
ative complications and any additional surgical intervention if
required.
Surgical technique
The surgical procedure consisted of AGV implantation
(models S2, S3, FP7, FP8) using a standardized surgical tech-
nique by a single experienced surgeon (SD). Surgery was
done after obtaining informed written consent under peribul-
bar or general anesthesia. After applying a superior rectus
bridle suture or corneal traction suture, a fornix-based con-
junctival flap and tenon’s capsule were dissected to allow
insertion of the plate of the implant into sub-tenon’s space
8 mm behind the corneal limbus. Before insertion of the
plate, the valve of the implant was primed with balanced salt
solution (BSS, Alcon, Fort Worth, TX, USA). The plate was
fixed to the sclera with 9–0 black nylon sutures (Ethicon,Alcon, Fort Worth, TX, USA). The tube was shortened to
the desired length with its sharp bevel facing anteriorly to
allow 2–3 mm of tube in anterior chamber. An anterior cham-
ber (AC) paracentesis wound was created at the peripheral
cornea and sodium hyaluronate 1% (Healon, Abbott Medi-
cal Optics) was injected to prevent collapse of the AC after
sclerostomy was made. To prevent tube movement, a radial
groove was made in the sclera at the proposed site & the
edges of the groove were retracted using mild cautery. The
tube of the implant entered the AC parallel to the iris plane
through the sclerostomy made with a 23 gauge syringe nee-
dle. For ease of entry, the needle was bent in a Z-shaped
manner. In pseudophakic patients with post-penetrating ker-
atoplasty (post-PK) glaucoma and peripheral anterior synech-
iae, the tube was placed in the ciliary sulcus. Concurrent
anterior or pars plana vitrectomy was performed in aphakic
patients and in patients in whom pars plana insertion of tube
was planned. The tube was fixed to the sclera with 9–0 black
nylon (Ethicon, Ethilon) suture. The anterior part of the tube
was covered with a donor scleral patch graft, which was then
fixed to the sclera with 9–0 black nylon sutures. The conjunc-
tiva was closed with 8–0 polyglactin suture (Vicryl; Ethicon,
Inc., Somerville, NJ, USA). The sodium hyaluronate in the
AC was removed as much as possible through the paracente-
sis site. No adjunctive antimetabolite was used in any of the
cases. Patients with neovascular glaucoma were treated with
panretinal photocoagulation and/or intravitreal bevacizumab
(Avastin, Genentech, South San Francisco, CA, USA) before
the AGV was implanted.
Postoperatively, all patients received intensive steroid,
antibiotic and cycloplegic drops daily. The antibiotic drops
were stopped at 2 weeks postoperatively, and steroid drops
were tapered gradually over 4–8 weeks.
All the parameters studied for the postoperative evalua-
tion were documented on each follow-up wherever possible
and decisions to start antiglaucoma medications or to per-
form other surgeries were taken accordingly.Success criteria
Success was defined as IOP >5 and <22 mmHg with or
without anti-glaucoma treatment. Failure was defined as
IOP <5 or >22 mmHg using every available glaucoma medi-
cation that the patient could topically or systemically toler-
ate17 (maximal medical therapy or MMT), need for
additional glaucoma surgery or loss of light perception.
Results of the most recent examination were used to record
the final IOP for classification as a success or failure. Preoper-
ative IOP was recorded on the most recent visit prior to sur-
gery. IOP was measured with a Goldmann applanation
tonometer, a handheld applanation tonometer (Kowa,
Kowa Optimet Inc., Torrance, CA, or Perkins, Clement
Clarke, Columbus, OH) or a Tono-pen (Mentor O & O, Nor-
well, MA).Statistics
Statistical analysis was done using the SPSS software
(Chicago, Illinois). The Kolmogorov–Smirnov test was used
to test for normality of numeric variables. For comparisons
of two normally distributed numerical variables, we used
paired Student’s t tests to determine any significant changes
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operatively. The cumulative success probability was deter-
mined using the Kaplan–Meier survival analysis based on
the aforementioned criteria. P values less than 0.05 were con-
sidered statistically significant.
Results
The baseline characteristics of the study sample are sum-
marized in Table 1. The mean age was 41.16 ± 19.41 years
(range 9–77 years). Forty-one patients (74.54%) were male
and 14 (25.46%) were female. The mean follow-up period
was 619 ± 384 days (range 90 days to 3 years). Before
implantation, eyes had been treated with an average of
1.58 ± 0.65 ocular procedures (Table 1). Of the three eyes
with neovascular glaucoma, two had proliferative diabetic
retinopathy and one had central retinal vein occlusion. Three
patients presented with congenital glaucoma with associated
aniridia and cataractous lens in one. Twenty-three patients
had undergone previous filtering surgery and 32 patients
had AGV implantation as a primary procedure. The tube
was positioned in AC in 39 eyes, pars plana in 2, and ciliary
sulcus in 14 eyes.
Of the 55 patients, 49 (89.09%) were considered success-
ful at the most recent follow-up as per the defined criteria
(Table 2). The mean pre-operative IOP was
39.71 ± 8.99 mmHg and 74.54% patients were on three or
more anti-glaucoma drugs. Post-operatively, the mean IOP
and number of medications used, at different time points
are described in Figs. 1 and 2, respectively. After the initial
postoperative reduction in medications, the mean number
of medications gradually increased over a period of time.
However, at any point of time it was less than the preopera-
tive requirement.
Of the 49 successful eyes, 95% required one or more anti-
glaucoma medications and 5% were not treated postopera-Table 1. Characteristics of patient population studied (n = 55).
Age in years (mean ± SD) 41.37 ± 22.88
Gender
Male (%) 41 (74.54)
Female (%) 14 (25.46)
Specific glaucoma diagnosis
Post-penetrating keratoplasty glaucoma 19 (34.55%)
Glaucoma post VR surgery 8 (14.55%)
Traumatic glaucoma 6 (10.91%)
Neovascular glaucoma 3 (5.45%)
Uveitic glaucoma 3 (5.45%)
Aphakic glaucoma 3 (5.45%)
ACIOL with secondary glaucoma 3 (5.45%)
Congenital glaucoma 3 (5.45%)
Advanced POAG 3 5.45%)
Advanced CACG 2 (3.64%)
Microphthalmos 1 (1.82%)
Malignant glaucoma 1 (1.82%)
Frequency of type of previous glaucoma surgery
Trabeculectomy ± Mitomycin C 18 (32.7%)
Trabeculotomy 3 (5.45%)
Combined cataract and trabeculectomy 2 (3.64%)
Lens status
Phakic 20 (36.36%)
Pseudophakic 24 (43.64%)
Aphakic 11 (20%)tively. The cumulative probability of success was 85.45% at
1 year and 79.63% at 3 years (Figs. 3 and 4).
Of the six eyes that had failed based on IOP criteria, there
was one each in neovascular, congenital, post-VR surgery and
malignant group while two in the post-PK category. How-
ever, subgroups were small and asymmetrical precluding sta-
tistical comparisons. The eyes that had failed underwent a
mean of 1.83 ± 0.40 prior incisional surgeries as compared
to 1.55 ± 0.67 in successful eyes. However, the difference
was not statistically significant (p = 0.30).
The mean IOP in eyes that had AGV implantation as the
primary procedure and prior failed filtering surgery was
16.59 ± 6.12 and 18.82 ± 4.97 mmHg respectively. The dif-
ference although clinically significant, was not statistically sig-
nificant (p = 0.15).
Among the failed eyes, two eyes suffered loss of light per-
ception; one developed retinal detachment, whereas three
required additional glaucoma surgery. However, the loss of
light perception in both the patients was determined to be
not directly related to AGV implantation.
The case of malignant glaucoma had a past history of com-
bined phacotrabeculectomy. Following AGV implantation,
the patient developed a shallow AC requiring IOL explanta-
tion and re-vitrectomy. However, during insertion of infusion
cannula, the surgery was complicated with suprachoroidal
hemorrhage and retinal detachment.
The patient with neovascular glaucoma was primarily a
case of central retinal vein occlusion. Tube implantation was
performed after failure of conventional filtering procedure.
Later, this patient developed progressive proliferative vitreo-
retinopathy with loss of IOP control and light perception.
One patient with congenital glaucoma with aniridia and
subluxated lens with a history of lens aspiration with vitrec-
tomy underwent trabeculotomy and trabeculectomy as a pri-
mary surgery. AGV implantation was performed in view of
uncontrolled IOP after failed filtering surgery in this patient.
The patient subsequently required trans-scleral photoabla-
tion for the control of IOP.
A hypertensive phase (HP) was defined as a rise in IOP to
>21 mm of Hg within 3 months of AGV implantation, after
reduction of IOP to <22 mmHg during the first postoperative
week and not caused by tube obstruction, tube retraction, or
malfunctioning of the valve.18 Resolution of the HP was
defined as an IOP <22 mmHg along with (1) a reduction of
the IOP by 3 mmHg or more with the same number of med-
ications or less or (2) reduction of at least one medication
with a change of IOP <3 mmHg. This phase was observed
between 1 and 3 months in 15/55 (27.27%) patients in our
study (Fig. 1). The peak mean IOP at 3 months postopera-
tively was significantly higher than that at 6 months
(P = 0.008). There was resolution of HP in 12 (80.0%) patients
in our series. No patient considered as successful, required
systemic antiglaucoma medication after the HP was over.
Moreover, none of our patients required secondary surgical
intervention to control the HP.
Visual acuity remained stable (within one Snellen line of
preoperative levels in cases wherever quantitative visual acu-
ity measurement was possible) or improved at last follow-up
in 47 cases (85.4%). Of the 8 patients, who had worse visual
acuity compared with the preoperative level, two actually lost
light perception, one developed retinal detachment, two had
cataract progression, and one suffered graft failure whereas
Table 2. Preoperative and postoperative (last follow-up) comparisons.
Preoperative Postoperative
IOP (mean ± SD mmHg) 39.71 ± 8.99 17.52 ± 5.72 P < 0.001
Antiglaucoma medication (mean ± SD) 3.27 ± 0.84 1.25 ± 0.88 P < 0.001
Visual acuity (logMAR units) 1.36 ± 0.55 1.37 ± 0.68 P = 0.919
Figure 1. Mean intraocular pressure after Ahmed glaucoma valve
implantation. The preoperative intraocular pressure of 39.71 ± 8.99
mmHg decreased to 10.80 ± 4.57 mmHg at 1 day, 18.6 ± 4.56 mmHg at
3 months (N = 55, P < 0.001), 15.74 ± 4.12 mmHg (N = 55, P < 0.001) at
6 months, 17.67 ± 6.45 mmHg (N = 38, P < 0.001) at 1 year and
18.94 ± 3.55 mmHg at 3 years (N = 19, P < 0.001) after surgery.
Figure 3. Kaplan–Meier life-table analysis. Cumulative probability of
success following AGV implantation was 85.45% at 1 year and 79.63% at
3 years.
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acuity at baseline was 1.36 ± 0.55 logarithm of the minimum
angle of resolution (logMAR) units and at the last follow-up
was 1.37 ± 0.68 logMAR units (P = 0.919) (Table 2).Complications
No major intra-operative complications occurred in any of
the patients. Fourteen (25.45%) patients developed post-
operative complications of which, seven (50%) required surgi-
cal intervention (Table 3). The most common post-operative
complication was hypotony i.e. IOP of 5 mm of Hg or less that
occurred in 6/55 (10.90%) patients. Two of these patients
presented with bullous choroidal detachment with shallow
AC requiring reformation.Figure 2. Number of drugs used at different time points. Number of
medications was reduced from 3.27 ± 0.84 in pre-operative period to
1.01 ± 0.75 (N = 55, P < 0.001) at 3 months, 0.92 ± 0.83 (N = 55,
P < 0.001) at 6 months, 1.02 ± 0.83 (N = 38, P < 0.001) at 1 year,
1.17 ± 0.92 at 2 years (N = 29, P < 0.001) and 1.57 ± 0.83 (N = 19,
P < 0.001) at 3 years.Two patients developed obstruction of the tube (one by a
vitreous tag and another by cortical matter) that required
anterior vitrectomy and cortical washout, respectively. One
patient with tube extrusion and conjunctival erosion required
tube repositioning and reinforcement with a scleral patch.
Another patient had conjunctival erosion and exposure of
sclera patch graft which responded to conservative treat-
ment with oral doxycycline, corticosteroids, and tear substi-
tutes.19 Two post-PK patients had tube-corneal touch in the
early postoperative period. One of these eyes subsequently
developed corneal decompensation requiring repeat kera-
toplasty. Other complications included, one eye with corneal
graft infiltrates unrelated to surgery and another with a reti-
nal detachment. None of our patients developed motility dis-
order, wound leak, bleb related infections or encapsulation.Discussion
AGV is a shunt device with a flow restriction mechanism
that is used in difficult glaucomas either as a primary surgical
option or after failure of conventional filtration proce-
dures.20–26 Most case series have reported success ratesFigure 4. Follow-up percentage at different time points.
Table 3. Post-operative complications.
Complication No. of
patients
Surgical
intervention
Post-operative
hypotony ± choroidal effusion
6 2
Graft failurea 1 1
Tube obstruction 2 2
Tube erosion 1 1
Tube corneal toucha 2
Phthisis bulbi 1
Retinal detachmentb 1
Suprachoroidal hemorrhageb 1
Conjunctival erosion 1
Motility disorder 0
Bleb related infections 0
Wound leak 0
Loss of light perceptiona 2
Malignant Glaucomaa 1 1
a More than one complication may have occurred in an eye.
b Complication was unrelated to surgery.
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define success and lengths of follow-up.18,21 Our study
reported the success rate of AGV implantation to be 89.1%
which is comparable to the published data.27
In our study, AGV implant reduced the pre-operative mean
IOP of 39.71 ± 8.99 mmHg to 17.52 ± 5.72 (p < 0.001) and
dependency on anti-glaucoma medications from 3.27 ± 0.84
pre-operatively to 1.25 ± 0.88 (p < 0.001) at final follow up
visit which is comparable to other studies.2,3 (Table 2).
The cumulative probability of success was 85.45% at
1 year and 79.63% at 3 years which is comparable to various
published case series. A North Indian study reported a suc-
cess rate of 86.91% at 12 months and 83.76% at 24 months.2
Huang et al.27 reported a success rate of 88% and Lima et al.3
reported it to be 70.5%.
A HP is a frequent finding after placement of AGV.28 In a
report by Ayyala and associates, this ‘hypertensive phase’
(HP) occurred in 82% of the cases (70 of 85 patients).28
Nouri-Mahdavi et al. reported the incidence of a HP to be
56.4% in their series.18 Resolution of the HP occurred in 19
of 68 eyes (28%) in their study with available data. Panda
et al. reported a HP in 80% of eyes between 1 and 3 months
that was resolved with anti-glaucoma medications.20 The inci-
dence of a hypertensive phase with the silicone implant has
been reportedly lower than with the polypropylene implant
36.4% versus 48.5%, respectively.29 The HP (27.27%) in our
study might have been minimized because of more frequent
use of silicone implants and postoperative antiglaucoma
medications in these eyes.
In the present study, the incidence of post-operative com-
plications was 25.45%. Transient hypotony in the post-opera-
tive period is a common finding, more so with the non-valved
implants. Valved implants open at a specific IOP level, thus
having a lower chance of post-operative hypotony. The inci-
dence of hypotony (10.90%) in our study compares favorably
with other studies.30 In our study, a total of 6 patients devel-
oped post-operative hypotony, of which 4 had spontaneous
resolution. However, none of them had wound leaks as a
cause.
One of the patients with post-PK glaucoma developed
graft failure due to tube-corneal touch. The incidence of
tube-corneal touch was much lower in our patients as com-
pared to other studies.2,31 The reason for this might be thatmost of the post-PK patients were pseudophakic with periph-
eral anterior synechiae, thereby prompting us to place the
tube in the ciliary sulcus. This reduces the likelihood of
tube-corneal touch.
Obstruction of the tube is a known complication following
GDD surgery and occurred in 2 patients.32 One of the
patients, who developed obstruction of the tube due to a vit-
reous tag, was post-trauma and phakic with suspected infe-
rior zonular dialysis. However, there was no vitreous in the
AC at the time of implantation. On the fourth postoperative
day, the vitreous tag advanced from the suspected zonular
dialysis and blocked the tube. It was removed successfully
by anterior vitrectomy. The other patient who developed
blockade of the tube had undergone PK with ECCE/IOL
6 months prior to implantation and had no visible cortex at
the time of surgery. Cortical material did appear post-opera-
tively, which required removal to relieve the obstruction.
Tube erosion has been well reported in the literature.33,34
A standard of care to prevent tube erosion is with the use of a
patch graft. Common materials used include pericardium,
sclera, fascia lata, and cornea.35 Tube erosion occurred in
one patient in our series, requiring repositioning with rein-
forcement. The lower incidence could be explained by the
use of a scleral patch graft providing tectonic strength and
protection against tube erosion.
Implant endplate size and its biomaterial have been con-
sidered to play a role in the final effect of GDDs on IOP con-
trol. Ishida et al. showed probabilities of success of 94.2% at
12 months and 82.4% at 24 months for the silicone plate
group, and 83.2% at 12 months and 56. 7% at 24 months,
for the polypropylene plate group.29 In their series, Tenon’s
cysts that required needling or surgical excision were
observed in 4.5% with silicon AGV implantation in compari-
son to 18.2% with polypropylene device. The polypropylene
material may be the reason for the high risk of failure due to
encapsulation in these cases.
We did not encounter any case of encapsulation in our
study. This could possibly be explained due to less frequent
use of polypropylene implants (20%) as compared to silicone
AGV (80%).
Although formal motility testing was not performed, we
did not encounter clinically-relevant motility disorders in
any of our patients. The reason might be the placement of
the implant in the superotemporal quadrant in most of our
patients.36,37
The major limitation of our study is its retrospective
design. Secondly, we had more patients in groups with
post-PK glaucoma and glaucoma post-VR surgery as com-
pared to other groups, so we could not compare the success
rate of AGV implantation and risk factors for failure in various
groups.
These series of patients are unique in that the patients were
operated by a single surgeon, with a consistent technique.
They were followed without significant secondary interven-
tions such as needling or 5-fluorouracil injection. The results
in terms of the IOP control, visual acuity and the complication
rate in the series were satisfactory. The majority of the postop-
erative complications related to implant were resolved either
spontaneously or with simple surgical procedures.
In conclusion, Ahmed glaucoma valve implantation has a
good success rate in terms of IOP control and dependency
over antiglaucoma medications and has low incidence of
108 S. Dubey et al.complications. So, this surgery can be considered as a rela-
tively safe and effective treatment modality for refractory
glaucomas in Northern Indian Eyes.Conflict of interest
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